Edara Lokesh, Suvvari Tarun Kumar, Kutikuppala Lakshmi Venkata Simhachalam
Internal Medicine, Western Michigan University, Kalamazoo, USA.
Medicine, Rangaraya Medical College, Kakinada, IND.
Cureus. 2020 Dec 27;12(12):e12330. doi: 10.7759/cureus.12330.
Coronavirus disease 2019 (COVID-19) can lead to severe respiratory failure; about 5%-10% of patients progress to severe pneumonia and respiratory distress, leading to multi-system failure. Dexamethasone helped to prevent mortality in COVID-19 patients. Low resource population in developing countries has limited access to critical care, but they do have access to oral and IV corticosteroids, anti-hyperglycemic agents, and anticoagulants. We report two patients with severe COVID-19 successfully treated with a high dose of methylprednisolone therapy. Early intervention with high dose corticosteroids in COVID-19 patients could be a solution for pacifying cytokine storms and reducing morbidity and mortality.
2019冠状病毒病（COVID-19）可导致严重呼吸衰竭；约5%-10%的患者会进展为重症肺炎和呼吸窘迫，进而导致多系统衰竭。地塞米松有助于预防COVID-19患者的死亡。发展中国家资源匮乏的人群获得重症监护的机会有限，但他们可以使用口服和静脉注射皮质类固醇、抗高血糖药物和抗凝剂。我们报告了两名重症COVID-19患者成功接受大剂量甲泼尼龙治疗的病例。对COVID-19患者早期使用大剂量皮质类固醇进行干预可能是平息细胞因子风暴、降低发病率和死亡率的一种解决方案。
